© 2022 MJH Life Sciences™ and Managed Healthcare Executive. All rights reserved.
Laura Joszt
Articles
HRQOL Declined in Certain Areas for Patients With AD During the Pandemic
June 24, 2022
Article
Certain problems such as pain/discomfort, worrying and fear of the persistence/recurrence of atopic dermatitis (AD) became more common among patients with AD since the start of the COVID-19 pandemic.
Patients With Cancer Faced Heightened Economic, Social, Psychological Impacts From COVID-19
June 15, 2022
Article
A review of multiple studies found the COVID-19 exacerbated the economic, social and psychological difficulties that patients with cancer were already facing because of their cancer.
FDA Expands Approval of Dupixent to Children 6 Months and Older With Moderate-to-Severe Atopic Dermatitis
June 10, 2022
Article
Dupixent was already approved for patients 6 years and older. The new approval makes the drug available to children 6 months to 5 years whose atopic dermatitis is inadequately controlled.
Dupixent Safe, Effective Over 52 Weeks in Adolescents With Moderate-to-Severe AD
June 01, 2022
Article
A 52-week open-label extension study supported the long-term use of Dupixent to treat adolescents with moderate-to-severe atopic dermatitis.
Disadvantaged Communities Face the Biggest Adverse Impacts From Climate Change
May 26, 2022
Article
Although climate change affects the entire global population, historically marginalized and under-resourced communities will be disproportionately affected.
Real-World Evidence Corroborates Dupixent Clinical Trials in Atopic Dermatitis
May 25, 2022
Article
Data gathered from electronic medical records found that the results in a real-world patient population with atopic dermatitis were consistent with those found in clinical trials.